Arvinas, Inc. remains a key player in the emerging PROTAC protein degrader space, with several clinical-stage assets targeting oncology and neurodegeneration. Despite stable revenue near $260 million in 2025, the company continues to incur substantial operating losses reflective of heavy R&D and commercial investments. Recent workforce reductions aim to streamline operations but could impact commercialization efforts, particularly for its partnered breast cancer candidate, vepdegestrant. Strategic collaborations underpin development progress but also introduce execution risks amid regulatory and financial uncertainties.